✨ Your Portfolio is fetched and updated from zerodha.
Small CDMO

Aarti Pharmalabs Ltd.

AARTIPHARM

Market Cap
₹5,838 Cr.
P/E
33.42

Aarti Pharmalabs Ltd.

  • Aarti Pharmalabs
  • Supriya Lifescience
  • IOL Chem & Pharma

FAQs on Aarti Pharmalabs Ltd. Shareprice

Aarti Pharmalabs has given better returns compared to its competitors.
Aarti Pharmalabs has grown at ~22.64% over the last 3yrs while peers have grown at a median rate of 18.6%

Yes, Aarti Pharmalabs is expensive.
Latest PE of Aarti Pharmalabs is 34.06, while 3 year average PE is 25.09.
Also latest EV/EBITDA of Aarti Pharmalabs is 17.19 while 3yr average is 15.94.

View FAQ's On Business

Growth Table

  • Aarti Pharmalabs Ltd.
  • Supriya Lifescience
  • IOL Chem & Pharma

Balance Sheet

  • Aarti Pharmalabs Ltd.
  • Supriya Lifescience
  • IOL Chem & Pharma

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Aarti Pharmalabs Ltd.
  • Supriya Lifescience
  • IOL Chem & Pharma

Cash Flow

  • Aarti Pharmalabs Ltd.
  • Supriya Lifescience
  • IOL Chem & Pharma

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Aarti Pharmalabs Ltd.
  • Supriya Lifescience
  • IOL Chem & Pharma

Quarterly Results

  • Aarti Pharmalabs Ltd.
  • Supriya Lifescience
  • IOL Chem & Pharma

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Aarti Pharmalabs Ltd. Financials

Balance sheet of Aarti Pharmalabs is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Aarti Pharmalabs is increasing.
Latest net debt of Aarti Pharmalabs is ₹676 Crs as of Mar-26.
This is greater than Mar-25 when it was ₹379 Crs.

The profit is oscillating.
The profit of Aarti Pharmalabs is ₹179 Crs for TTM, ₹272 Crs for Mar 2025 and ₹217 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Aarti Pharmalabs latest dividend payout ratio is 16.64% and 3yr average dividend payout ratio is 12.85%

Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Capital Work in Progress

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech